ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 16.04% |
| Q2 2025 | -54.77% |
| Q1 2025 | 203.97% |
| Q4 2024 | 0.37% |
| Q3 2024 | -7.76% |
| Q2 2024 | 28.29% |
| Q1 2024 | -15.17% |
| Q4 2023 | 40.13% |
| Q3 2023 | -29.86% |
| Q2 2023 | 98.89% |
| Q1 2023 | 18.38% |
| Q4 2022 | -14.29% |
| Q3 2022 | 72.51% |
| Q2 2022 | 0.00% |
| Q1 2022 | 0.00% |